A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies (MDX1106-03)

Clinical Trial ID NCT00730639

PubWeight™ 129.29‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00730639

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 52.99
2 Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010 17.13
3 Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015 11.98
4 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
5 Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014 8.11
6 Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2015 4.68
7 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
8 From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012 2.46
9 Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol 2015 2.30
10 The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) 2015 2.17
11 Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015 1.67
12 Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2014 1.59
13 Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 2015 1.23
14 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
15 Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res 2013 1.12
16 New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015 1.02
17 The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentation. Cancer Res 2012 1.01
18 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
19 Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J 2014 0.88
20 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
21 PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther 2014 0.85
22 PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2014 0.85
23 Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother 2015 0.83
24 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
25 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
26 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
27 Therapeutic challenges in renal cell carcinoma. Am J Clin Exp Urol 2015 0.80
28 Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol 2014 0.79
29 Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract 2011 0.79
30 New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics 2016 0.79
31 Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 2015 0.78
32 Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies. PLoS One 2013 0.78
33 Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2011 0.78
34 Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. ESMO Open 2016 0.77
35 Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. J Transl Med 2016 0.77
36 Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs 2014 0.76
37 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
38 Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev 2016 0.76
39 The role of checkpoints in the treatment of GBM. J Neurooncol 2015 0.75
Next 100